We report a case of an anaplastic lymphoma kinase (ALK) fusion‐positive non‐small‐cell lung cancer patient who developed severe hemolytic anemia after starting low‐dose alectinib due to liver failure from diffuse liver metastasis. This evidence concerns the gene ALK and liver failure.